| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/06/2006 | US20060148791 Glutamate receptor antagonists |
| 07/06/2006 | US20060148774 Hypoglycemic agent |
| 07/06/2006 | US20060148769 (20S)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin D3 and their uses |
| 07/06/2006 | US20060148768 Vitamin d3 lactone derivatives |
| 07/06/2006 | US20060148760 Method for the sysnthesis of compounds of formula I and their uses thereof |
| 07/06/2006 | US20060148754 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 07/06/2006 | US20060148739 Method of evaluating compound efficacious in treating obesity |
| 07/06/2006 | US20060148720 Use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
| 07/06/2006 | US20060148713 Use of exendins and agonists thereof for the reduction of food intake |
| 07/06/2006 | US20060148692 Novel protein and its dna |
| 07/06/2006 | US20060148030 Nuclear receptor err y 3 |
| 07/06/2006 | US20060147609 Oilseed processing |
| 07/06/2006 | US20060147565 Purified amylase inhibitor and novel process for obtaining the same |
| 07/06/2006 | US20060147496 Diagnosis of irritable bowel disorders; fibromyalgia; chronic fatique syndrome; antidepressants; tinnitus; autism; autoimmune disease; Crohn's disease; quantitative analysis of serotonine, bile acid in sample |
| 07/06/2006 | US20060147446 Humanized antibodies to human GP39, compositions, and therapeutic uses thereof |
| 07/06/2006 | US20060147437 Use of pigmented retinal epithelial cells for creation of an immune privilege site |
| 07/06/2006 | US20060146644 System for producing micro-cluster liquids |
| 07/06/2006 | DE112004001572T5 Verfahren Method |
| 07/06/2006 | CA2592858A1 Substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their preparation and use in medicaments |
| 07/06/2006 | CA2592832A1 Substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| 07/06/2006 | CA2592532A1 Sesamin/episesamin compositions with improved bioavailability |
| 07/06/2006 | CA2591912A1 Pyrimidinylisoxazole derivatives |
| 07/06/2006 | CA2590681A1 N-[(4, 5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, sulfonamide, carbamate and urea) derivatives as cannabinoid cb1 receptor antagonists |
| 07/06/2006 | CA2590586A1 Substituted biaryl analogues |
| 07/06/2006 | CA2588941A1 5ht2c receptor modulator compositions and methods of use |
| 07/05/2006 | EP1676862A1 Recombinant antibody against human insulin-like growth factor |
| 07/05/2006 | EP1676841A1 Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments |
| 07/05/2006 | EP1676833A1 Propionic acid derivatives useful in the treatment of lipid disorders |
| 07/05/2006 | EP1676581A2 Polymer compositions for use in therapy |
| 07/05/2006 | EP1676488A2 Compositions and methods for body weight management |
| 07/05/2006 | EP1675833A1 1h-imidazole derivatives as cannabinoid receptor modulators |
| 07/05/2006 | EP1675820A2 Propionic acid derivatives useful in the treatment of lipid disorders |
| 07/05/2006 | EP1675625A1 Mechanism-based targeted pancreatic beta cell imaging and therapy |
| 07/05/2006 | EP1675617A1 Compositions and methods for augmenting kidney function |
| 07/05/2006 | EP1675604A1 Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii) |
| 07/05/2006 | EP1675547A2 Glucocerebroside treatment of disease |
| 07/05/2006 | EP1490360A4 Thiazolidinedione derivatives and pharmaceutical composition comprising the same |
| 07/05/2006 | EP1399441B1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 07/05/2006 | EP1390049B1 Compositions for treating animal diseases and syndromes comprising transfer factor |
| 07/05/2006 | EP1250328B1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 07/05/2006 | EP1102838B1 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 07/05/2006 | CN2792500Y Oral insulin corpuscle |
| 07/05/2006 | CN1798831A Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains |
| 07/05/2006 | CN1798735A 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase |
| 07/05/2006 | CN1798732A Substituted tetralins and indanes |
| 07/05/2006 | CN1796558A Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof |
| 07/05/2006 | CN1796419A Dressed and modified sugar of monosaccharide/disaccharide |
| 07/05/2006 | CN1796396A Crystal of amido sugar |
| 07/05/2006 | CN1796382A A category of compound of new macrolide, preparation method and application |
| 07/05/2006 | CN1796370A Compound substitution heterocycle class |
| 07/05/2006 | CN1795919A Honeyed pills of pure Chinese traditional medicine for reducing blood fat and decreasing blood pressure |
| 07/05/2006 | CN1795884A Ginseng calcium |
| 07/05/2006 | CN1795881A Composite of total flavone phosphatide of seabuckthorn, and preparation method |
| 07/05/2006 | CN1795873A Antler calcium |
| 07/05/2006 | CN1795851A Application of compound of esters of piperic acid in preparing hypolipidemic or health products |
| 07/05/2006 | CN1795848A Magnesium preparation of conjugate linoleic acid and preparation method |
| 07/05/2006 | CN1795846A Peroral solid preparation of metformin hydrochloride and preparation method |
| 07/05/2006 | CN1795736A Quick dissolving roselle tea bag |
| 07/05/2006 | CN1262547C Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative |
| 07/05/2006 | CN1262541C Tricyclic protein kinase inhibitors |
| 07/05/2006 | CN1262309C Remedies for diseases in association with decreasing in bone mass |
| 07/05/2006 | CN1262307C Health food for diabetes patients |
| 07/05/2006 | CN1262291C Medicine for treating diabetes and its vascular complications and preparation method thereof |
| 07/05/2006 | CN1262282C Preparing method and use for Chinese medicine extractive with alpha-glucosidal inhibiting activity |
| 07/05/2006 | CN1262277C Injection of low molecular weight chondroitin sulfate and its preparation method |
| 07/05/2006 | CN1262274C Complexes of phosphate derivatives |
| 07/05/2006 | CN1262273C Chinese rose extract and its preparing method and use |
| 07/05/2006 | CN1262213C Water containing soluble fiber |
| 07/05/2006 | CN1262212C Health care beverage |
| 07/04/2006 | US7071358 Lipid diseases; metabolism diosrders; antiproliferative agents |
| 07/04/2006 | US7071344 Vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments |
| 07/04/2006 | US7071332 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 07/04/2006 | US7071300 IGF antagonist peptides |
| 07/04/2006 | US7071234 Administering racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate for prophylaxis or therapy |
| 07/04/2006 | US7071231 Especially Type II diabetes; stimulating the kinase activity of the insulin receptor; activating the insulin receptor |
| 07/04/2006 | US7071229 Oxidation of ursolic acid ; reduction at low temperature |
| 07/04/2006 | US7071221 Heterocyclic oxime compounds |
| 07/04/2006 | US7071218 N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases |
| 07/04/2006 | US7071213 Cannabinoid receptor ligands |
| 07/04/2006 | US7071210 Mixtures of cholesteryl ester transfer protein (CETP) inhibitor such as torcetrapib and calcium channel blockers, angiotensin converting enzyme inhibitors, diuretics or adrenergic blocking agents use for cardiovascular disorders |
| 07/04/2006 | US7071208 β3 Adrenergic agonists |
| 07/04/2006 | US7071207 Suppression appetite; induction weight loss |
| 07/04/2006 | US7071202 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| 07/04/2006 | US7071195 Especially amino- or amido-ethyltetralin derivatives |
| 07/04/2006 | US7071193 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases |
| 07/04/2006 | US7071187 Naphthyridine derivatives |
| 07/04/2006 | US7071185 Treating schizophrenia with no weight-gain side effects; 5-HT2c recptor agonist; bipolar disorder; antidepressants; anxiolytic agents; panic attack; agoraphobia; antiepileptic agents; sleep disorders; migraines; sexual dysfunction |
| 07/04/2006 | US7071183 Use of inhibitors of the renin-angiotensin system |
| 07/04/2006 | US7071179 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 07/04/2006 | US7071178 Bone disorders; osteoporosis |
| 07/04/2006 | US7071177 P-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents |
| 07/04/2006 | US7071160 Integrin binding polipeptide for diagnosis, prevention and treatment of renal failure, thrombosis, osteoporosis, cancers and diabetes |
| 07/04/2006 | US7070971 enzyme inhibitor for selectin mediated binding events and methods of treating disease conditions using animal models; genetic engineering |
| 07/04/2006 | US7070953 foods, feeds, cosmetics; fish extarct; agreegable taste, flavor, odor; incubating aqueous slurry; extraction |
| 07/04/2006 | US7070812 Process for producing dry powders of one or more carotenoids |
| 07/04/2006 | US7070805 Comprises a pharmacologically active ingredient, a sugar and a low-substituted hydroxypropylcellulose having 5 to 7% by weight of hydroxypropyl group; fast disintegrability, suitable strength and no roughness |
| 07/04/2006 | CA2404848C Indole carboxylic acids as thyroid receptor ligands |
| 07/04/2006 | CA2364719C 2-aminopyridines containing fused ring substituents |
| 07/04/2006 | CA2332066C Tetrazole compounds as thyroid receptor ligands |
| 07/04/2006 | CA2233285C Pyrazolopyrimidines as crf receptor antagonists |